Johnson & Johnson (NYSE:JNJ) Updates FY 2019 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.60. The company issued revenue guidance of $80.8-81.6 billion, compared to the consensus revenue estimate of $81.22 billion.Johnson & Johnson also updated its FY19 guidance to $8.53-8.63 EPS.

A number of research analysts have recently commented on the company. BMO Capital Markets assumed coverage on Yelp in a research note on Wednesday, April 17th. They issued an outperform rating for the company. Zacks Investment Research upgraded Jack Henry & Associates from a sell rating to a hold rating in a research note on Wednesday, March 27th. Royal Bank of Canada raised their target price on Johnson Service Group from GBX 180 ($2.35) to GBX 190 ($2.48) and gave the company an outperform rating in a research note on Tuesday. Bank of America upgraded First Horizon National from an underperform rating to a neutral rating and set a $16.00 target price for the company in a research note on Tuesday. Finally, Goldman Sachs Group set a $27.00 target price on Melco Resorts & Entertainment and gave the company a buy rating in a research note on Tuesday, May 28th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has an average rating of Buy and an average price target of $150.33.

JNJ stock opened at $131.86 on Thursday. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The company has a market cap of $351.79 billion, a price-to-earnings ratio of 16.12, a PEG ratio of 2.29 and a beta of 0.70. The company’s 50 day moving average is $138.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter last year, the company earned $2.10 EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 8.59 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 11th. The stock was acquired at an average price of $139.68 per share, with a total value of $419,040.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How to interpret a stock’s beta number

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.